The Importance of IL8 Gene Expression and IL-8 A251T in Diagnosis and Prognosis of Ovarian Cancer in Iraqi Women

Khaled A. Habeb¹* and Maysaa Ghazi. Jumaah²

¹Department of Biology, College of Science for Women, University of Baghdad, Baghdad, Iraq.
²Department of Microbiology, College of Medicine, University of Maisan, Maisan, Iraq.

Correspondence: Khaled A. Habeb, Department of Biology, College of Science for Women, University of Baghdad, Baghdad, Iraq.

Received: 02 Oct 2022; Accepted: 10 Nov 2022; Published: 15 Nov 2022

Citation: Habeb KA, Jumaah MG. The Importance of IL8 Gene Expression and IL-8 A251T in Diagnosis and Prognosis of Ovarian Cancer in Iraqi Women. Cancer Sci Res. 2022; 5(3): 1-7.

ABSTRACT

The present study aimed to shed light on the association between the gene expression of IL8 and its genetic polymorphism IL-8 A251T in the incidence and pathogenesis of ovarian cancer. A total of 43 Paraffin-embedded tissue blocks from patients with different stages of newly diagnosed ovarian cancer were provided by certain Iraqi hospitals as well as 14 samples of patients with benign ovarian tumors tissues as a control group were used in this study. In the present study, the level of IL8 gene expression was investigated by comparing it with that of benign tumors, the results detected that IL-8 mRNA was expressed in 47(81.02%) of samples, 36 samples with ovarian cancer and 11 benign ovarian. IL-8 mRNA levels in ovarian cancer tissues were statistically significant higher than those in benign ovarian tissue (P=0.0328<0.05). The samples were divided into high and low mRNA-expression depending on the mean value of IL8 gene expression in benign tumors which used as a cutoff, the results showed that samples with high mRNA-expressing 25(69.4%) which showed high significant differences compare with samples that showed low expressing 11(30.55%) (P value=0.0028<0.01). In correlation with histopathological type of ovarian tumors, mucinous tumors showed statistically significant difference in compare with other histopathologic tumor type (P=0.0516,<0.05). According to the tumor stages, statistically significant difference was found between 31(86.11%) of samples with stage I which showed the highest level of expression and 5(13.88%) of samples with stage III (P value=0.0410<0.05). For A251T polymorphism, the result showed that 21(58.33%) patients were heterozygous A/T, 14(38.88%) were homozygous T/T, and 1(2.77%) was homozygous A/A. For patients with benign ovarian tumors 11(91.66%) were heterozygous A/T, 1(8.33%) was homozygous T/T, and no one of the patients were homozygous for the A/A genotype. High significant prevalence of the IL-8 251T allele was detected in both ovarian cancer patients (P value 0.0047 <0.01) and patients with benign ovarian tumors (P value 0.014 <0.02) as compared with IL-8 251A allele. In the present study the association of the A251T polymorphism with ovarian cancer were investigated by attending to levels of IL-8 mRNA in benign and malignant ovarian tissues related with the respective genotypes. In benign ovarian tumors statically analysis showed that there were no significant differences between genotypes, while for cancer samples, the average of IL-8 gene expression in ovarian cancer patients carrying +251TT genotype was highly significant than that in ovarian cancer patients with the +251AT and +251AA genotypes (p value= 0.0037<0.01). In conclusion, the results reflected the possibility of detecting the IL8 gene transcript in benign as well as the malignant ovarian tissues but with wide differences in the sample percentages and level of gene expression which in turn reflect the value of IL8 gene as a useful tool for discriminating malignant breast tumors from non-malignant ones. On the other hand the high level of gene expression associated with stage I of tumor may be reveals the diagnostic value of this gene for early diagnosis of ovarian cancer. The results showed that the genetic variation of IL-8 gene influences susceptibility to ovarian cancer, we also suggested that the TT genotype of IL-8 -251A/T may associate with increase the risk of ovarian cancer in Iraqi women because of altered IL-8 gene expression.
Keywords
Ovarian cancer, Gene expression, IL-8, IL-8 A251T.

Introduction
IL-8 is a member of the CXC chemokine family and is classified and referred to as CXCL8 according to the new nomenclature systems [1]. Transcription of the IL-8 gene encodes for a protein of 99 amino acids that is subsequently processed to yield a signaling competent protein of either 77 amino acids in nonimmune cells or 72 amino acids in monocytes and macrophages. IL-8 belongs to a super family of chemokines that has chemotactic activity for neutrophils, eosinophils, basophils, monocytes, mast cells, dendritic cells, nature killer (NK) cells, and T and B lymphocytes [2]. The chemokine are divided into four subgroups, CXC, CC, CX3C and C chemokines, in which C indicates NH2-terminal cysteines and X indicates intervening amino acid, respectively [1]. The gene encoding cytokine IL-8/CXCL8 is found on human chromosome 4, q12-21, and consists of four exons and three introns [3]. IL-8 binds to two distinct receptors, CXCR1 and CXCR2, with a similar high affinity [4] CXCR1 and CXCR2 have been shown to be expressed in a variety of cells, such as leukocytes, endothelial cells and malignant cells [5]. The biologic effect of IL-8 originally described includes chemotaxis for a variety of leukocytes, facilitating leukocyte transmigration into the tissue by inducing adhesion molecule expression and promoting neutrophil adhesion to extracellular matrix, activating various functions of neutrophil, including degranulation and the release of leukotrienes B4 and platelet-activating factors [6]. Evidence has revealed that IL-8 has several biologic functions not related to leukocyte chemotaxis and migration and may play an important role in cancer progression. Tumor associated IL-8 expression was first found in malignant melanoma cell lines, and its expression was considered to play a role in regulating the growth and metastasis of melanoma [7]. Tumor associated IL-8 is thought to play at least five roles in the biology of primary and metastatic cancers [8], including control leukocyte infiltrate into tumor tissue, modification of tumor immune response, regulation of angiogenesis, autocrine or paracrine, regulation of tumor growth and survivals, and promoting tumor cell migration. Evidence shows that IL-8 biologic activity in tumors and the microenvironment may contribute to cancer progression, and in other circumstances to host anti-tumor response, and this biologic response may be different in different types of human cancers [9]. Some studies have shown that IL-8 was constitutively expressed in several human cancer cell lines derived from astrocytoma, hepatoma, transitional cell carcinoma, and melanoma, and is associated with angiogenesis and metastatic potential in human melanoma cell lines in a nude mice model [10]. IL-8 is also a well-known chemotactic factor for leukocytes, and leukocytes infiltration is frequently seen in some types of human cancers, including NSCLC. These recruited inflammatory cells can enhance angiogenesis by secreting several cytokines, such as tumor necrotic factor (TNF)-α. Thus, in addition to its direct angiogenic effect, IL-8 secreted by tumor cells might also indirectly induce angiogenesis by recruiting inflammatory cells to the tumor tissues [11]. IL-8 expression can be induced by various stimuli, such as lipopolysaccharides, cytokines (IL-1, TNF-α), and bacterial or viral products, while IL-8 is also constitutively expressed in many human cancers [12]. Other stimuli can also regulate constitutive IL-8 expression in tumors. IL-8 expression has been shown to be up-regulated by inflammatory cytokines and ultraviolet light in melanoma, and downregulated by interferon (INF)-α and INF-β. Accumulating evidence generated in clinical studies shows increased tumoral IL-8 expression correlates with adverse patient prognosis in a variety of human cancers. Another study has shown that IL-8 expression is associated with a poor prognosis in epithelial-ovarian cancer patients [13]. Although a wide variety of cytokines can be measured in ovarian cancer ascites, interleukin-6 (IL-6) and interleukin-8 (IL-8) are among the most abundant. The concentration of these pro-inflammatory cytokines in ascites is 40- to 500-fold higher as compared to the levels found in serum [14]. The source of the IL-8 found in ascites has not been well defined. These pro-inflammatory cytokines are involved in different pathophysiological processes including carcinogenesis. IL-8 that was recently reported to promote ovarian tumor growth in vivo [15]. In the present study, we aimed to shed light on the role and importance of IL8 gene expression and its particular polymorphism IL-8 A251T as a tool for diagnosis and prognosis of ovarian cancer.

Materials and Methods
Subjects and samples collection: The tissue samples used in this study included 43 Paraffin-embedded tissue blocks from patients with different stages of newly diagnosed invasive ovarian cancer were provided by certain Iraqi hospitals (including Al-Kadhemia, AL-Yarmouk Teaching Hospital, Baghdad Hospital, the Teaching Laboratories of Medical City, Nuclear Medical Hospital in Baghdad and Alsadler Hospital in Missan) after patients underwent to total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO), subtotal abdominal hysterectomy, vaginal hysterectomy, and endometrial biopsy, 14 samples of patients with benign ovarian tumors tissues were used as a control. The required information about the patients and the histopathologic properties of the tumors were recorded from the patients’ files. The Paraffin-embedded tissue blocks were sectioned into 10μm in DNase-RNase tubes for molecular evaluation. Samples subjected to RNA extraction and molecular study by using Revers Transcription and Real Time PCR at Molecular Oncology Unit in Guy’s hospital – Kings college/London.

RNA extraction, reverse transcription
Total RNA was extracted from benign and malignant tumor tissues and normal tumors was extracted using the RNeasy FFPE Kit, which designed for purifying total RNA from FFPE tissue sections (Qiagen-USA) according to the protocol provided by the manufacturer. Total RNA was reversely transcribed using Thermo-Script™ Reverse Transcription kit (Invitrogen/USA). The procedure was carried out in a reaction volume of 50 μl composed of 15 μl Denaturized RNA, 0.2 μl Random hexamere primers 3μg/μl, 5μl of 10 mM dNTP Mix, 10μl of 5x cDNA synthesis buffer, 2.5μl RNase OUT (40U/μl), 2.5μl ThermoScript RT (15 units/μl),
14.8 µl DEPC-treated water. The samples were then placed in a 96 Well Thermal Cycler, and cycled at the following conditions: 25°C for 10 min., 10 min. at 37°C, and 60 min. at 42°C followed by 75°C for 5 minutes. The converted cDNA. Was stored at -80°C and used as a template for PCR amplification of VEGF. Primers and probes were designed using Primer Express software (ABI, USA). The primers and prop for IL8 were as follows: 5’ CCAGGGCGTGGCTTCTTGTG3’ (forward), 5’GCCTTGCAAAACTGACACCT3’ (reverse), 5’CGGCCCTCCTGATTTTCTGCAGCTCT- GTG -3’ (prop), PGK1 gene was used as an endogenous control gene. The amplification of IL8 cDNA for real-time PCR analysis was performed in duplicate using the Applied Bio systems 7900. The 25 µl of reaction volume containing 10 µl of master mix , 3 µl of primer mixes, 3 µl of RNase free water and 4 µl of cDNA template. Real-Time PCR protocol was as follows; stage 1 50°C for 1 minute, (stage 2: 95°C for 45 sec., 55°C for 45 sec. and 72°C for 1 min.) repeated for 32 cycles. The slope of a standard curves was used to estimate the PCR amplification efficiency of a real-time PCR reaction. A calculation for estimating the efficiency (E) of a real-time PCR assay was performed as following: 

\[ E = \frac{(10^{-\text{slope}} - 1)}{100} \]

\[ E = \frac{(10^{-3.35} - 1)}{100} \]

For each sample, the cycle threshold (Ct) is defined as the number of PCR cycles required to achieve the user defined level of fluorescence. This Ct value is used to compare across all samples. The Ct is inversely proportional to the amount of starting mRNA of the target gene (IL8) as well as the endogenous control gene (PGK1). The relative fold change ratio of the target gene in the sample was calculated as described below:

\[ \text{Log copy}_{\text{endogenous control gene}} = \frac{(Ct - 32.85)}{3.3592} \]

\[ \text{Copy number}_{\text{endogenous control gene}} = 10^{\text{Log copy}} \]

\[ \text{Log copy}_{\text{IL8}} = \frac{(Ct - 34.82)}{3.5126} \]

\[ \text{Copy number}_{\text{IL8}} = 10^{\text{Log copy}} \]

\[ \text{Fold change} = \frac{\text{Copy number}_{\text{IL8}}}{\text{Copy number}_{\text{endogenous control gene}}} \]

**DNA Extraction, Genotyping and Sequencing Analysis**

DNA was extracted and purified from Formalin-Fixed Paraffin-Embedded (FFPE) tissue sections of 58 ovarian tumor samples with QIAamp DNA FFPE Tissue Mini Kit (Qiagen, USA) which was designed for purifying of DNA from FFPE tissue sections. The primers for IL-8 A251T were as follows: 5’- TTGTTCTAACACCTGCCACTCT-3’ (forward) and 5’- TGACCCGTGGCTCTTG-3’ (reverse). The procedure was carried out in a reaction volume of 20 µl. The PCR conditions were as follows: an initial step of 10 min at 95°C fo enzyme activation, followed by 40 cycles of 94°C for 30 s, 58°C for 30 s, 72°C for 30 s for denaturation, annealing and extension respectively, followed by final extension for 5 min. at 72°C, and then incubation at 4°C to time end. The resulting DNA fragments were separated by 2% agarose gel electrophoresis and visualized under UV light after ethidium staining. Before sequencing the PCR products purified by using Charge Switch PCR Clean-up kit according to the manufacturer’s instructions, the sequencing performed using ABI BigDye terminator ready reactions Kit (Applied Biosystems, USA) and ABI Automated DNA Sequencer 3730. Data were analyzed using Mutation Surveyor Software of sequencing reading Version 3.24.

**Statistical Analysis**

The Statistical Analysis System-SAS (2012) program was used to effect of difference factors in study parameters. Chi-square test was used to significant compare between percentage and Least significant difference – LSD test was used to significant compare between means in this study.

**Results**

A total of 58 samples of 44 patients with ovarian cancer and 14 benign ovarian tumors tissues were examined for the expression of IL8 rt-PCR. The patients’ age range was 14-70 years and the median is 47 years. According to the family history, all samples were negative for family history to the ovarian cancer. Clinical features of ovarian cancer samples are listed in table 1. About the menopausal state of ovarian cancer patients, 20(46.5%) of samples were premenopausal, while 23(53.48%) of them were postmenopausal. According to the International Federation of Gynecology and Obstetrics (FIGO) surgical staging system, most of samples 35(61.4%) came with stage I, while the other 23(81.02%) were with stage III. According to the tumor histological types, the samples were divided into three clinical groups; surface epithelial tumors 38(88.3%) samples, sex cord tumors 3(6.9%) samples, and germ cell tumors 2(4.65%) samples. qRT-PCR analysis revealed that IL8mRNA was expressed in the tissues of both malignant and benign tumors (figure 1). The present study showed that IL8 mRNA was expressed in 47(81.02%) of samples, 36 samples with ovarian cancer and 11 benign ovarian. The higher level IL8 mRNA in ovarian cancer samples was statistically significant (Mean ± SE: 8.68 ± 2.49, P=0.0328<0.05) compared to benign tumors (Mean ± SE: 1.99 ± 0.84). The mean value of IL8 gene expression in benign tumors was used as a cutoff to separate tumors into high and low mRNA-expressing samples which showed high statistically significant differences (P value = 0.0028<0.01) between high mRNA-expressing 25(69.4%), and low mRNA-expressing samples 13(30.5%). In correlation with the histopathological type of ovarian tumors mucinous tumors showed statistically significant difference in the level of IL-8 gene expression (Mean ± SE: 11.37 ± 9.90, P=0.0516,<0.05) compared with other histopathologic tumor type. According to the tumor stages, statistically significant difference was found between 31(86.11%) of samples with stage I which showed the highest level of expression (Mean ± SE: 8.38 ± 3.48, P value=0.0410<0.05) and 5(13.88%) samples with stage III (Mean ± SE: ± 2.58 ± 0.71). The results of genotyping in benign and ovarian cancer patients viewed in (table 2). The result of IL-8 A251T polymorphism showed that out of 36 ovarian cancer patients 21(58.33%) patients were heterozygous A/T, 14(38.88%) patients were homozygous T/T, and 1(2.77%) were homozygous A/A (figure 2). For patients with benign ovarian tumors, 11 patients(91.66%) were heterozygous A/T, one patient (8.33%) was homozygous T/T, and no one of the patients were homozygous for the A/A genotype. High significant prevalence of the IL-8 251T
that there was no correlation between angiogenic gene expression and clinical outcomes, as reported in other studies.

In the present study, the level of IL-8 gene expression was investigated by comparing it with that of benign tumors. IL-8 mRNA was expressed in 47(81.02%) of samples, 36 samples with ovarian cancer and 11 benign ovarian. IL-8 mRNA levels in ovarian cancer tissues were statistically significant higher. Kassim et al. showed in his study, which was performed on 24 tumors from patients with epithelial ovarian cancer and 20 tissue samples of benign ovarian lesions as a control group that IL-8 mRNA was expressed only in 18.2% of 44 samples he tested. There are difficulties in discussing the differences that had been showed between benign and malignant tumors because most of the studies for IL-8 gene expression were performed either using techniques other than qRT-PCR like in situ hybridization or immunohistochemistry (IHC) or the experiments were applied on animal models, cell line and malignant tumors without comparing with benign tumors, ovarian cancer types, and epithelial ovarian tumor subtypes. Using the mean value of IL-8 gene expression in benign tumors as the cutoff value to showed high significant differences (P value 0.0047 <0.01) and patients with benign ovarian tumors (P value 0.014 <0.02) as compared with IL-8 251A allele. In compare with IL-8 gene expression, the study showed that the average of IL-8 gene expression in ovarian cancer patients carrying +251TT genotype was highly significant (p value= 0.0037<0.01) than that in ovarian cancer patients with the +251AT and +251AA genotypes. While in benign ovarian tumors statistically analysis showed that there were no significant differences between genotypes. The analysis of the distribution of the three IL-8 A251T genotypes in correlation with stages of cancer showed that for patients with stage I the percentages of these genotypes were 61%, 39%, and 0% for the genotypes AT, TT, and AA respectively. While for patients with stage III, the percentages of these genotypes were 43%, 43%, and 14% for these genotypes. The AT genotypes in patients with stage I showed highly statistically significant among other genotypes (P value 0.00043 < 0.001).

Discussion

In the present study, the level of IL-8 gene expression was investigated by comparing it with that of benign tumors. IL-8 mRNA was expressed in 47(81.02%) of samples, 36 samples with ovarian cancer and 11 benign ovarian. IL-8 mRNA levels in ovarian cancer tissues were statistically significant higher. Kassim et al. showed in his study, which was performed on 24 tumors from patients with epithelial ovarian cancer and 20 tissue samples of benign ovarian lesions as a control group that IL-8 mRNA was expressed only in 18.2% of 44 samples he tested. There are difficulties in discussing the differences that had been showed between benign and malignant tumors because most of the studies for IL-8 gene expression were performed either using techniques other than qRT-PCR like in situ hybridization or immunohistochemistry (IHC) or the experiments were applied on animal models, cell line and malignant tumors without comparing with benign tumors, ovarian cancer types, and epithelial ovarian tumor subtypes. Using the mean value of IL-8 gene expression in benign tumors as the cutoff value to showed high significant differences (P value 0.0047 <0.01) and patients with benign ovarian tumors (P value 0.014 <0.02) as compared with IL-8 251A allele. In compare with IL-8 gene expression, the study showed that the average of IL-8 gene expression in ovarian cancer patients carrying +251TT genotype was highly significant (p value= 0.0037<0.01) than that in ovarian cancer patients with the +251AT and +251AA genotypes. While in benign ovarian tumors statistically analysis showed that there were no significant differences between genotypes. The analysis of the distribution of the three IL-8 A251T genotypes in correlation with stages of cancer showed that for patients with stage I the percentages of these genotypes were 61%, 39%, and 0% for the genotypes AT, TT, and AA respectively. While for patients with stage III, the percentages of these genotypes were 43%, 43%, and 14% for these genotypes. The AT genotypes in patients with stage I showed highly statistically significant among other genotypes (P value 0.00043 < 0.001).

Discussion

In the present study, the level of IL-8 gene expression was investigated by comparing it with that of benign tumors. IL-8 mRNA was expressed in 47(81.02%) of samples, 36 samples with ovarian cancer and 11 benign ovarian. IL-8 mRNA levels in ovarian cancer tissues were statistically significant higher. Kassim et al. showed in his study, which was performed on 24 tumors from patients with epithelial ovarian cancer and 20 tissue samples of benign ovarian lesions as a control group that IL-8 mRNA was expressed only in 18.2% of 44 samples he tested. There are difficulties in discussing the differences that had been showed between benign and malignant tumors because most of the studies for IL-8 gene expression were performed either using techniques other than qRT-PCR like in situ hybridization or immunohistochemistry (IHC) or the experiments were applied on animal models, cell line and malignant tumors without comparing with benign tumors, ovarian cancer types, and epithelial ovarian tumor subtypes. Using the mean value of IL-8 gene expression in benign tumors as the cutoff value to showed high significant differences (P value 0.0047 <0.01) and patients with benign ovarian tumors (P value 0.014 <0.02) as compared with IL-8 251A allele. In compare with IL-8 gene expression, the study showed that the average of IL-8 gene expression in ovarian cancer patients carrying +251TT genotype was highly significant (p value= 0.0037<0.01) than that in ovarian cancer patients with the +251AT and +251AA genotypes. While in benign ovarian tumors statistically analysis showed that there were no significant differences between genotypes. The analysis of the distribution of the three IL-8 A251T genotypes in correlation with stages of cancer showed that for patients with stage I the percentages of these genotypes were 61%, 39%, and 0% for the genotypes AT, TT, and AA respectively. While for patients with stage III, the percentages of these genotypes were 43%, 43%, and 14% for these genotypes. The AT genotypes in patients with stage I showed highly statistically significant among other genotypes (P value 0.00043 < 0.001).

Discussion

In the present study, the level of IL-8 gene expression was investigated by comparing it with that of benign tumors. IL-8 mRNA was expressed in 47(81.02%) of samples, 36 samples with ovarian cancer and 11 benign ovarian. IL-8 mRNA levels in ovarian cancer tissues were statistically significant higher. Kassim et al. showed in his study, which was performed on 24 tumors from patients with epithelial ovarian cancer and 20 tissue samples of benign ovarian lesions as a control group that IL-8 mRNA was expressed only in 18.2% of 44 samples he tested. There are difficulties in discussing the differences that had been showed between benign and malignant tumors because most of the studies for IL-8 gene expression were performed either using techniques other than qRT-PCR like in situ hybridization or immunohistochemistry (IHC) or the experiments were applied on animal models, cell line and malignant tumors without comparing with benign tumors, ovarian cancer types, and epithelial ovarian tumor subtypes. Using the mean value of IL-8 gene expression in benign tumors as the cutoff value to showed high significant differences (P value 0.0047 <0.01) and patients with benign ovarian tumors (P value 0.014 <0.02) as compared with IL-8 251A allele. In compare with IL-8 gene expression, the study showed that the average of IL-8 gene expression in ovarian cancer patients carrying +251TT genotype was highly significant (p value= 0.0037<0.01) than that in ovarian cancer patients with the +251AT and +251AA genotypes. While in benign ovarian tumors statistically analysis showed that there were no significant differences between genotypes. The analysis of the distribution of the three IL-8 A251T genotypes in correlation with stages of cancer showed that for patients with stage I the percentages of these genotypes were 61%, 39%, and 0% for the genotypes AT, TT, and AA respectively. While for patients with stage III, the percentages of these genotypes were 43%, 43%, and 14% for these genotypes. The AT genotypes in patients with stage I showed highly statistically significant among other genotypes (P value 0.00043 < 0.001).
chronic periodontitis, mainly in those who presented the TA genotype. However the results of the current study showed completely different results, they revealed that IL-8 mRNA expression in samples with the TT genotype of 251A/T was significantly greater than samples with the AT or AA. These results were similar to that reported by Selvaraj et al.,[27] who showed that normal healthy subjects and pulmonary tuberculosis positive for TT genotype showed significantly higher IL-8 production compared to the AA genotype. The study suggests that the TT genotype may be associated with higher IL-8 production and increased leucocyte accumulation and inflammation at the site of Mycobacterium tuberculosis infection. Ahn et al.,[28] also showed that IL-8 protein level in bronchoalveolar lavage fluid was significantly increased in the subjects with idiopathic pulmonary fibrosis having the common allele (T) of IL8251A/T compared to those with the minor allele (A). This result indicates that the 251T allele within the promoter may result in increased IL-8 production when compared with the minor allele. These differences in our results may be due to the conclusion that there are two major haplotypes containing the –251A allele, only one of which is associated with disease and increased IL-8 production, as a result the –251A allele may not be the functional one and it may be in linkage disequilibrium with a functional variant elsewhere in the IL-8 gene [29]. Moreover, the reporter plasmid constructs containing 1409 base pairs of the 5’ flanking region of IL-8 gene differing only at the –251 position transfected into A549 cells, showed a higher expression for (–251T) than (–251A) constructs when stimulated with TNF in vitro [30]. These findings suggest that the –251T allele, in association with other functional variants in the IL-8 gene, may be involved in higher IL-8 production. According to the knowledge, the present study is the first study on the association of the IL-8 gene -251 T>A polymorphism and ovarian cancer risk in association with level of IL-8 mRNA. The results of this study showed that the genetic variation of IL-8 gene influences susceptibility to ovarian cancer. the results of the present study suggest that the TT genotype of IL-8 -251A/T may associate with increase the risk of ovarian cancer because of altered IL-8 gene expression.

Table 1: Clinical features of ovarian cancer samples.

<table>
<thead>
<tr>
<th>Age groups</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>children age 0-14 years</td>
<td>2 (4.65%)</td>
</tr>
<tr>
<td>Teenagers and young adults aged 15-24 years</td>
<td>1 (2.32%)</td>
</tr>
<tr>
<td>Adults aged 25-49 years</td>
<td>16 (37.2%)</td>
</tr>
<tr>
<td>Adults aged 50-74 years</td>
<td>24 (55.8%)</td>
</tr>
<tr>
<td>Menopausal state</td>
<td></td>
</tr>
<tr>
<td>premenopausal no. (%)</td>
<td>20 (46.5%)</td>
</tr>
<tr>
<td>postmenopausal no. (%)</td>
<td>23 (53.48%)</td>
</tr>
<tr>
<td>Family history</td>
<td></td>
</tr>
<tr>
<td>Positive no. (%)</td>
<td>0</td>
</tr>
<tr>
<td>Negative no. (%)</td>
<td>43 (100%)</td>
</tr>
<tr>
<td>FIGO surgical stage</td>
<td></td>
</tr>
<tr>
<td>Stage I no. (%)</td>
<td>35 (81.4%)</td>
</tr>
<tr>
<td>Stage III no. (%)</td>
<td>8 (18.6%)</td>
</tr>
<tr>
<td>Tumor histological types</td>
<td></td>
</tr>
<tr>
<td>Surface epithelial tumors</td>
<td>38 (88.37%)</td>
</tr>
<tr>
<td>Sex cord tumors</td>
<td>3 (6.9%)</td>
</tr>
<tr>
<td>Germ cell tumors</td>
<td>2 (4.65%)</td>
</tr>
</tbody>
</table>

Figure 1: Amplification target and endogenous gene product run with duplicate samples Cycle number is plotted on the x-axis with level of fluorescence on the y-axis. The threshold fluorescence level is depicted by the green line.
Acknowledgments
The authors thank all patients for their permission to get samples and clinical information, we also thank the head and staff members of the molecular oncology department / Guys hospital / London, for their cooperation in part of the study related with molecular analysis.

References